4//SEC Filing
Avoro Capital Advisors LLC 4
Accession 0000902664-23-004754
CIK 0001042074other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 12:53 PM ET
Size
18.6 KB
Accession
0000902664-23-004754
Insider Transaction Report
Form 4
Avoro Capital Advisors LLC
10% Owner
Transactions
- Sale
Put Option (obligation to buy)
2023-09-13$0.98/sh−250$246→ 250 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-13Exp: 2023-10-20→ Common Stock (25,000 underlying) - Sale
Put Option (obligation to buy)
2023-09-13$1.10/sh−950$1,041→ 950 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-13Exp: 2023-10-20→ Common Stock (95,000 underlying) - Sale
Put Option (obligation to buy)
2023-09-12$1.00/sh−1,500$1,500→ 1,500 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-12Exp: 2023-10-20→ Common Stock (150,000 underlying) - Sale
Put Option (obligation to buy)
2023-09-12$1.00/sh−300$299→ 300 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-12Exp: 2023-10-20→ Common Stock (30,000 underlying) - Purchase
Pre-funded Warrant (right to buy)
2023-09-12$17.13/sh+583,771$9,999,939→ 583,771 total(indirect: See footnotes)Exercise: $0.00→ Common Stock (583,771 underlying)
Aghazadeh Behzad
10% Owner
Transactions
- Sale
Put Option (obligation to buy)
2023-09-12$1.00/sh−1,500$1,500→ 1,500 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-12Exp: 2023-10-20→ Common Stock (150,000 underlying) - Sale
Put Option (obligation to buy)
2023-09-12$1.00/sh−300$299→ 300 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-12Exp: 2023-10-20→ Common Stock (30,000 underlying) - Sale
Put Option (obligation to buy)
2023-09-13$0.98/sh−250$246→ 250 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-13Exp: 2023-10-20→ Common Stock (25,000 underlying) - Sale
Put Option (obligation to buy)
2023-09-13$1.10/sh−950$1,041→ 950 total(indirect: See footnotes)Exercise: $17.00From: 2023-09-13Exp: 2023-10-20→ Common Stock (95,000 underlying) - Purchase
Pre-funded Warrant (right to buy)
2023-09-12$17.13/sh+583,771$9,999,939→ 583,771 total(indirect: See footnotes)Exercise: $0.00→ Common Stock (583,771 underlying)
Footnotes (3)
- [F1]The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
- [F2]The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
- [F3]Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after September 14, 2023, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein and all other warrants beneficially owned by the Reporting Persons contain an exercise limitation prohibiting the holder from exercising the Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, none of the warrants beneficially owned by the Reporting Persons are presently exercisable.
Documents
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001633313
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 12:53 PM ET
- Size
- 18.6 KB